AliveCor stock
Private-market facts for current and former AliveCor employees researching their stock.
Overview
AliveCor makes KardiaMobile, FDA-cleared personal ECG devices that allow consumers and clinicians to record medical-grade electrocardiograms from a smartphone to detect atrial fibrillation and other heart conditions.
Selling AliveCor shares
Why shareholders consider selling
Shareholders in AliveCor may explore liquidity for a number of reasons — diversifying a concentrated position, funding a personal financial goal, or simply reducing exposure to a single private holding. As a private company, AliveCor does not trade on a public exchange, meaning employees and early shareholders cannot simply sell through a brokerage. Extended private timelines can leave shareholders waiting years for an exit event, which is why some choose to explore secondary-market options.
Can you sell AliveCor stock?
Whether a shareholder can sell typically depends on what they hold and how it was acquired. Vested and exercised shares are generally more straightforward than unexercised options or unvested RSUs. Most private companies, including those in the Healthcare & Biotech sector, impose transfer restrictions such as rights of first refusal or board approval requirements. The specific terms governing AliveCor shares would be outlined in the holder's equity agreement or the company's governing documents.
What affects the value of AliveCor shares?
The price a buyer is willing to pay for private shares is shaped by several factors: overall demand for the stock, the company's financial performance, broader Healthcare & Biotech market conditions, and any recent private-market transaction activity. Data points such as the company's Series E round can help frame expectations, though they do not guarantee a transaction price.
What should holders check before selling
- The type of security held (common shares, preferred, options, RSUs)
- Whether the equity is fully vested and, for options, whether it has been exercised
- Any transfer restrictions, lock-up provisions, or company approval requirements
- Estimated net proceeds after applicable taxes and transaction fees
- Whether partial liquidity — selling a portion rather than the full position — may be a better fit
Tools for AliveCor shareholders
Exploring equity in AliveCor often raises questions about taxes, exercise timing, valuation, and exit outcomes. These tools can help you model different decisions using your own assumptions.
Latest funding round
AliveCor most recently raised a Series E round . Total funding raised to date is approximately $233M.
Lead investors in this round include OMRON Ventures and Khosla Ventures.
Founders & company background
AliveCor was founded in 2010 by Dave Albert and is headquartered in Mountain View, CA.
Investors
Industry
Similar private companies
Latest AliveCor news
Frequently asked questions
- Is AliveCor still a private company?
- Yes, AliveCor is currently a private company.
- What is AliveCor's latest funding round?
- AliveCor's most recent known round is Series E.
- What is AliveCor's valuation?
- AliveCor's valuation has not been publicly disclosed.
- Who are the investors in AliveCor?
- Notable investors include OMRON Ventures, Khosla Ventures, Mayo Clinic.
- Can I sell my AliveCor stock?
- Private company shares can sometimes be sold on secondary markets. Speaking with a specialist who understands AliveCor stock can help you evaluate your options.
Related pages
Last verified: 2026-04-13 · AliveCor data compiled from funding disclosures, investor announcements, corporate filings, and public records.
Information on this page is compiled from publicly available sources and may be outdated or incomplete. This is not investment advice. Consult a qualified advisor before making financial decisions.